pentobarbital will decrease the level or result of buprenorphine buccal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will decrease the extent or impact of stiripentol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If struggling to prevent coadministration of stiripentol with solid CYP3A4 inducers, enhance stiripentol dose.
pentobarbital will reduce the extent or impact of pimavanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. Stay clear of coadministration if at all possible. Keep track of for lessened pimavanserin efficacy. A rise in pimavanserin dosage could possibly be essential.
Contraindicated (one)pentobarbital will minimize the extent or result of dienogest/estradiol valerate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Women must not opt for estradiol valerate/dienogest as their contraceptive when employing robust CYP3A4 inducers due to probable lower in contraceptive efficacy.
To minimize the possibility of overdosage or the development of dependence, Restrict the prescribing and dispensing of sedative-hypnotic barbiturates, to the quantity expected for your interval until the following appointment
pentobarbital will reduce the level or result of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
As medical data regarding the utilization of pentobarbital all through breastfeeding are missing, it truly is sensible to think about different brokers, particularly when nursing a newborn or preterm infant.[seventeen]
pentobarbital will reduce the level or impact of ambrisentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Mysterious.
pentobarbital will reduce the level or outcome of conjugated estrogens, vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will decrease the level or outcome of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Solid or reasonable CYP3A inducers could lower cobimetinib systemic exposure by >80% check here and cut down its efficacy.
pentobarbital will lower the level or influence of zolpidem by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Not known.
pentobarbital will increase toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. CYP3A4 inducers might enhance the metabolism of ifosfamide to its Energetic alkylating metabolites.
pentobarbital will lessen the extent or impact of clarithromycin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Mysterious.
pentobarbital will lower the level or influence of dasatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.